Early data from first participating employer show that SmartRx can save organizations millions by bypassing traditional PBMs to deliver brand-name GLP-1 medications NEW YOR K, April 23, 2026 Noom Health, the enterprise division of the leading behavior change platform Noom, today announced that its Smart Rx program is on pace to cut GLP-1 medication costs by nearly 80% for its first participating employer, projecting approximately $1.3M in annual spend compared to $6.2M in the prior year
This article explains what patients should know about KPV peptide benefits, including inflammation signaling, gut health, immune balance, current research limits, and the questions to ask before considering any peptide-related treatment plan
Smaller spreads make it easier to profit from short-term moves
IDD is a leading cause of chronic lower back pain with pathological mechanisms involving nucleus pulposus cell (NPC) apoptosis, extracellular matrix (ECM) degradation, an imbalanced inflammatory microenvironment and oxidative stress damage (12,13)
Lillys phase 2 retatrutide trial achieved up to 17.5% mean weight reduction at 24 weeks
A newly identified peptide called CAQK takes a different approach entirely
